Host-pathogen pyrimidine metabolism drives cystic fibrosis lung disease
A study published in Nature Communications reveals that pyrimidine metabolism is a key driver of lung remodeling in cystic fibrosis patients. The research shows that both host cells and the pathogen Pseudomonas aeruginosa use this metabolic pathway to sustain infection and tissue damage.
Why it matters
Identifying this shared metabolic axis offers a potential target for new therapeutic interventions to treat cystic fibrosis.
Nature Communications ( 2026 ) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in